107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.

Journal Article

Current therapies for glioblastoma are limited by ineffective delivery beyond the blood-brain barrier, limited diffusion of regionally-delivered macromolecules, and lack of tumor specificity. Sustained direct intracerebral infusion at slow flow rates [convection-enhanced delivery (CED)] can overcome delivery barriers. PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. We are reporting results of an ongoing phase I study evaluating PVSRIPO via CED delivery.

Full Text

Duke Authors

Cited Authors

  • Sampson, JH; Desjardins, A; Peters, KB; Ranjan, T; Vlahovic, G; Lally-Goss, D; Threatt, S; Herndon, J; Friedman, AH; Friedman, H; Bigner, D; Gromeier, M

Published Date

  • August 2013

Published In

Volume / Issue

  • 60 Suppl 1 /

Start / End Page

  • 155 -

PubMed ID

  • 23839374

Electronic International Standard Serial Number (EISSN)

  • 1524-4040

Digital Object Identifier (DOI)

  • 10.1227/01.neu.0000432699.02392.a4

Language

  • eng

Conference Location

  • United States